Description
Abstract
This paper reviews the current evidence on disease burdens
and likely future growth among patients in the ‘moderate’
group. New drug therapy can provide leverage for low cost
improvements in programmes.
£25.00
Author(s): N Bosanquet
This paper reviews the current evidence on disease burdens
and likely future growth among patients in the ‘moderate’
group. New drug therapy can provide leverage for low cost
improvements in programmes.
Author(s): J Seymour & C Lamers
Author(s): Z. Walker
Author(s): J. Clarke
Author(s): M Marshall
Author(s): R. McShane
Author(s): Dr Jonathan Hewitt
